Skyrizi and Rinvoq Momentum Continues, but Valuation Already Priced In

What happened

The Zacks article highlights strong Q1 growth for Skyrizi and Rinvoq, lifting 2026 sales outlooks and sustaining momentum through new indications. AbbVie's DeepValue report, which gives the stock a WAIT rating at $225, already assumes these two drugs deliver ~$31.6B combined in 2026 as the core of the post-Humira transition. While the news confirms demand-led share capture, it does not alter the key underwriting uncertainties: the conditional nature of Rinvoq's exclusivity to 2037 and the risk of payer access friction. Aesthetics remains a drag, with Juvederm still declining, and the base case already prices in smooth execution. Without a catalyst that materially shifts the probability of hitting the ~$67B revenue algorithm, the current entry offers limited margin of safety.

Implication

The Zacks article adds no new information beyond the guidance already provided. The DeepValue analysis highlights that the stock already discounts successful execution of the immunology transition, with a base-case target of $235. Key risks include Rinvoq exclusivity conditions, payer pushback, and aesthetics weakness. Until these uncertainties resolve or the stock pulls back to the attractive entry of $210, waiting provides a better risk/reward.

Thesis delta

No material shift. The news confirms the existing narrative and does not change the investment thesis. The DeepValue report's WAIT rating remains appropriate as the stock trades near the base-case fair value, with asymmetric downside if the immunology framework misses.